drugset / Trial / NCT05059587
Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is intended to evaluate the efficacy and safety of MBA-P01 compared to BOTOX in treatment of glabellar lines.
Timeline
- Start
- 2021-08-30
- Primary completion
- 2021-12-29
- Completion
- 2022-03-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | — | Other |
| Subject | MBA-P01 | Protein / enzyme biologic | — | Other |
Indications
No indication recorded.